fluxapyroxad: carboxamide; succinate dehydrogenase inhibitor
fluxapyroxad : An aromatic amide obtained by formal condensation of the carboxy group of 3-(difluoromethyl)-1-methylpyrazole-4-carboxylic acid with the amino group of 3',4',5'-trifluorobiphenyl-2-amine. Used to control a number of cereal fungal pathogens including those belonging to the Ascomycetes, Basidiomycetes and Zygomycetes families.
ID Source | ID |
---|---|
PubMed CID | 16095400 |
CHEBI ID | 83113 |
SCHEMBL ID | 167627 |
MeSH ID | M000598194 |
Synonym |
---|
n-(2-(3,4,5-trifluorophenyl)phenyl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide |
3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1h-pyrazole-4-carboxamide |
n-(3',4',5'-trifluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1h-pyrazole-4-carboxamide |
n-(3',4',5'-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methyl-1h-pyrazole-4-carboxamide |
3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluorobiphenyl-2-yl)-1h-pyrazole-4-carboxamide |
3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide |
fluxapyroxad |
907204-31-3 |
fluxapyroxad [iso] |
3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluoro(1,1'-biphenyl)-2-yl)-1h-pyrazole-4-carboxamide |
unii-7u8p4nar2s |
7u8p4nar2s , |
xemium |
SCHEMBL167627 |
CHEBI:83113 |
DTXSID6058215 |
AKOS027322014 |
3-(difluoromethyl)-1-methyl-n-[2-(3,4,5-trifluorophenyl)phenyl]pyrazole-4-carboxamide |
fluxapyroxad, pestanal(r), analytical standard |
fluxapyroxad 100 microg/ml in acetonitrile |
Z1552164593 |
EX-A1676 |
3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluoro-[1,1'-biphenyl]-2-yl)-1h-pyrazole-4-carboxamide , |
AS-36599 |
Q15632875 |
mfcd22373628 |
3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluorobiphenyl-2-yl)-1h-pyrazole-4-carboxamide; xemium |
3-(difluoromethyl)-1-methyl-n-(3 inverted exclamation marka,4 inverted exclamation marka,5 inverted exclamation marka-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide |
HY-135549 |
CS-0113442 |
1h-pyrazole-4-carboxamide, 3-(difluoromethyl)-1-methyl-n-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)- |
AC-36586 |
3-(difluoromethyl)-1-methyl-n-{3',4',5'-trifluoro-[1,1'-biphenyl]-2-yl}-1h-pyrazole-4-carboxamide |
EN300-264529 |
1ST000820 |
Fluxapyroxad (FLU) is a succinate dehydrogenase inhibitor (SDHI) fungicide. It protects crops from fungal diseases, but it has been identified as toxicants to aquatic organisms.
Excerpt | Reference | Relevance |
---|---|---|
"Fluxapyroxad (FLU) is a succinate dehydrogenase inhibitor that protects crops from fungal diseases, however, it has been identified as toxicants to aquatic organisms. " | ( Effects of embryonic exposure to fluxapyroxad on zebrafish (Danio rerio) ocular development. Chen, X; Li, W; Qiu, T; Wang, L; Xiao, P, 2022) | 2.45 |
"Fluxapyroxad (FLU) is a succinate dehydrogenase inhibitor (SDHI) fungicide used in controlling crop diseases. " | ( Transcriptional responses of fluxapyroxad-induced dysfunctional heart in zebrafish (Danio rerio) embryos. Guo, S; Li, W; Miao, N, 2022) | 2.46 |
"Fluxapyroxad (FLU) is a broad spectrum pyrazole-carboxamide SDHI fungicide and its potential impacts on fish embryonic development are unknown." | ( Fluxapyroxad induces developmental delay in zebrafish (Danio rerio). Li, W; Liu, X; Wu, Y; Yuan, M, 2020) | 2.72 |
"Fluxapyroxad is a broad-spectrum and high-efficiency succinate dehydrogenase inhibitor fungicide that can control plant fungal pathogens on many crops. " | ( Toxic effects and potential mechanisms of Fluxapyroxad to zebrafish (Danio rerio) embryos. Chen, J; Cui, F; Lin, F; Lin, H; Yuan, J, 2021) | 2.33 |
Excerpt | Reference | Relevance |
---|---|---|
" In this study, zebrafish embryos were exposed to fluxapyroxad to investigate the toxic effects and potential mechanisms of fluxapyroxad." | ( Toxic effects and potential mechanisms of Fluxapyroxad to zebrafish (Danio rerio) embryos. Chen, J; Cui, F; Lin, F; Lin, H; Yuan, J, 2021) | 1.14 |
" Despite its increasing use in modern agriculture and long-term retention in the environment, the potentially toxic effects of Flu in vivo, especially on neurodevelopment, remain under-evaluated." | ( The adverse effects of fluxapyroxad on the neurodevelopment of zebrafish embryos. Chen, J; Chen, S; Chen, Y; Li, H; Qiu, Y; Xia, S; Yu, H; Zhang, J; Zhao, Y; Zhu, J, 2022) | 1.03 |
Role | Description |
---|---|
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor | An EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor that interferes with the action of succinate dehydrogenase (quinone), EC 1.3.5.1. |
antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
biphenyls | Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. |
pyrazoles | |
trifluorobenzene | Any member of the class of fluorobenzenes carrying three fluorine substituents at unspecified positions. |
anilide fungicide | Any amide fungicide whose structure contains an anilide group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 14 (42.42) | 24.3611 |
2020's | 19 (57.58) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (47.08) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.03%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 32 (96.97%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |